{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:24Z","timestamp":1792783464870,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":114,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Health","award":["EY019014"],"award-info":[{"award-number":["EY019014"]}]},{"name":"National Institute of Health","award":["EY301163"],"award-info":[{"award-number":["EY301163"]}]},{"name":"Harold Amos Faculty Development Award"},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008556","name":"Paul MacKall and Evanina Bell MacKall Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019107","name":"Center for Advanced Retinal and Ocular Therapeutics, Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001205","name":"F. M. Kirby Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s13311-023-01364-6","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T22:38:59Z","timestamp":1679870339000},"page":"896-907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cell-Specific Expression of Human SIRT1 by Gene Therapy Reduces Retinal Ganglion Cell Loss Induced by Elevated Intraocular Pressure"],"prefix":"10.1016","volume":"20","author":[{"given":"Jipeng","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reas S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu T.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly E.","family":"Dine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi N.","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuala","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puya","family":"Aravand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahim","family":"Chaqour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Shindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-3121","authenticated-orcid":false,"given":"Ahmara G.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1007\/s13311-023-01364-6_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1007\/s13311-023-01364-6_bib2","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1007\/s13311-023-01364-6_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1590\/S0004-27492011000200001","article-title":"Managing glaucoma in developing countries","volume":"74","author":"Leite","year":"2011","journal-title":"Arq Bras Oftalmol"},{"issue":"2","key":"10.1007\/s13311-023-01364-6_bib4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0161-6420(02)01568-3","article-title":"Temba glaucoma study: a population-based cross-sectional survey in urban South Africa","volume":"110","author":"Rotchford","year":"2003","journal-title":"Ophthalmology"},{"issue":"1\u20132","key":"10.1007\/s13311-023-01364-6_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.2017.0041","article-title":"Targets of neuroprotection in glaucoma","volume":"34","author":"He","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"issue":"9422","key":"10.1007\/s13311-023-01364-6_bib6","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","article-title":"Primary open-angle glaucoma","volume":"363","author":"Weinreb","year":"2004","journal-title":"Lancet"},{"issue":"11","key":"10.1007\/s13311-023-01364-6_bib7","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00417-013-2464-7","article-title":"Global rates of glaucoma surgery","volume":"251","author":"Mansouri","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1007\/s13311-023-01364-6_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1034\/j.1600-0420.1999.770212.x","article-title":"The medium and long-term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open angle glaucoma","volume":"77","author":"Odberg","year":"1999","journal-title":"Acta Ophthalmol Scand"},{"issue":"18","key":"10.1007\/s13311-023-01364-6_bib9","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"11","key":"10.1007\/s13311-023-01364-6_bib10","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0161-6420(98)91134-4","article-title":"Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic","volume":"105","author":"Kosoko","year":"1998","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1007\/s13311-023-01364-6_bib11","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"6771","key":"10.1007\/s13311-023-01364-6_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35001622","article-title":"Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase","volume":"403","author":"Imai","year":"2000","journal-title":"Nature"},{"issue":"11","key":"10.1007\/s13311-023-01364-6_bib13","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1073\/pnas.110148297","article-title":"The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases","volume":"97","author":"Landry","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1007\/s13311-023-01364-6_bib14","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1073\/pnas.97.12.6658","article-title":"A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family","volume":"97","author":"Smith","year":"2000","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10.1007\/s13311-023-01364-6_bib15","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1167\/iovs.13-12157","article-title":"SIRT1 promotes RGC survival and delays loss of function following optic nerve crush","volume":"54","author":"Zuo","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1007\/s13311-023-01364-6_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/WNO.0b013e3181f7f833","article-title":"Oral resveratrol reduces neuronal damage in a model of multiple sclerosis","volume":"30","author":"Shindler","year":"2010","journal-title":"J Neuroophthalmol"},{"issue":"8","key":"10.1007\/s13311-023-01364-6_bib17","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1167\/iovs.07-0131","article-title":"SIRT1 activation confers neuroprotection in experimental optic neuritis","volume":"48","author":"Shindler","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1007\/s13311-023-01364-6_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/WNO.0000000000000760","article-title":"Effects of varying intranasal treatment regimens in ST266-mediated retinal ganglion cell neuroprotection","volume":"39","author":"Khan","year":"2019","journal-title":"J Neuroophthalmol"},{"key":"10.1007\/s13311-023-01364-6_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fneur.2012.00084","article-title":"Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis","volume":"3","author":"Fonseca-Kelly","year":"2012","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-023-01364-6_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-5960-2-3","article-title":"SIRT1 activating compounds reduce oxidative stress mediated neuronal loss in viral induced CNS demyelinating disease","volume":"2","author":"Khan","year":"2014","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"10.1007\/s13311-023-01364-6_bib21","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1167\/iovs.17-22972","article-title":"SIRT1 and NRF2 Gene transfer mediate distinct neuroprotective effects upon retinal ganglion cell survival and function in experimental optic neuritis","volume":"59","author":"McDougald","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1007\/s13311-023-01364-6_bib22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41434-021-00219-z","article-title":"Rescue of retinal ganglion cells in optic nerve injury using cell-selective AAV mediated delivery of SIRT1","volume":"28","author":"Ross","year":"2021","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-023-01364-6_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","article-title":"Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy","volume":"10","author":"Yang","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1007\/s13311-023-01364-6_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-4939-7407-8_3","article-title":"The microbead occlusion model of ocular hypertension in mice","volume":"1695","author":"Calkins","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1007\/s13311-023-01364-6_bib25","first-page":"e53731","article-title":"A magnetic microbead occlusion model to induce ocular hypertension-dependent glaucoma in mice","volume":"109","author":"Ito","year":"2016","journal-title":"J Vis Exp"},{"issue":"1","key":"10.1007\/s13311-023-01364-6_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mjafi.2015.12.001","article-title":"Glaucoma: The \u2018Black hole' of irreversible blindness","volume":"72","author":"Parihar","year":"2016","journal-title":"Med J Armed Forces India"},{"issue":"2\u20133","key":"10.1007\/s13311-023-01364-6_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.brainresbull.2009.04.004","article-title":"Rodent models of glaucoma","volume":"81","author":"Johnson","year":"2010","journal-title":"Brain Res Bull"},{"issue":"9","key":"10.1007\/s13311-023-01364-6_bib28","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1202584","article-title":"Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets","volume":"190","author":"Nimmagadda","year":"2013","journal-title":"J Immunol"},{"issue":"6","key":"10.1007\/s13311-023-01364-6_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/biom12060830","article-title":"Selective upregulation of SIRT1 expression in retinal ganglion cells by AAV-mediated gene delivery increases neuronal cell survival and alleviates axon demyelination associated with optic neuritis","volume":"12","author":"Ross","year":"2022","journal-title":"Biomolecules."},{"issue":"1","key":"10.1007\/s13311-023-01364-6_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1167\/iovs.09-3947","article-title":"The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice","volume":"51","author":"Sappington","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1007\/s13311-023-01364-6_bib31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.exer.2009.08.003","article-title":"Does elevated intraocular pressure reduce retinal TRKB-mediated survival signaling in experimental glaucoma?","volume":"89","author":"Guo","year":"2009","journal-title":"Exp Eye Res"},{"issue":"2","key":"10.1007\/s13311-023-01364-6_bib32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1523\/JNEUROSCI.3714-07.2008","article-title":"Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model","volume":"28","author":"Soto","year":"2008","journal-title":"J Neurosci"},{"issue":"11","key":"10.1007\/s13311-023-01364-6_bib33","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1523\/JNEUROSCI.4443-07.2008","article-title":"Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma","volume":"28","author":"Buckingham","year":"2008","journal-title":"J Neurosci"},{"issue":"8","key":"10.1007\/s13311-023-01364-6_bib34","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1167\/iovs.08-3267","article-title":"Brn3a as a marker of retinal ganglion cells: qualitative and quantitative time course studies in naive and optic nerve-injured retinas","volume":"50","author":"Nadal-Nicol\u00e1s","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01364-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01364-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01364-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:36:27Z","timestamp":1761806187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1878747923000247"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01364-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell-Specific Expression of Human SIRT1 by Gene Therapy Reduces Retinal Ganglion Cell Loss Induced by Elevated Intraocular Pressure","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01364-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}